3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Melanoma
3
Recurrence
2
Head and Neck Neoplasms
2
Carcinoma, Renal Cell
2
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioma
1
Ependymoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
ofatumumab
3
Vincristine
2
Rituximab
2
Lenalidomide
2
Bortezomib
2
tenofovir alafenamide
1
pomalidomide
1
pivalyloxymethyl butyrate
1
pegaspargase
1
nelarabine
1
immunotoxin HA22
1
fludarabine
1
bempegaldesleukin
1
Whole-Body Irradiation
1
Tablets
1
Panobinostat
1
Observation
1
Nivolumab
1
Mitoxantrone
1
Methotrexate
1
Mercaptopurine
1
Everolimus
1
Etoposide
1
Drug Therapy
1
Dexamethasone
1
DTRMWXHS-12
1
Cytarabine
1
Cyclophosphamide
1
Clofarabine
1
Cladribine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Leukemia, B-Cell
×
bempegaldesleukin
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts